Studies in preclinical NSCLC models have demonstrated that inhibition of CD47 using genetic or pharmacologic approaches impairs malignant phenotypes including tumor growth and immune escape, metastasis, stemness, and drug resistance. The gene discussed is CD47; the disease is neoplasm.